Literature DB >> 12468915

Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy.

Linda M S Resar1, Jodi B Segal, Lorna K Fitzpatric, Alison Friedmann, Saul W Brusilow, George J Dover.   

Abstract

This study was designed to determine if low doses of oral sodium phenylbutyrate (SPB) induce hemoglobin F (HbF) synthesis in children with hemoglobin SS (HbSS). We treated 8 children with HbSS over a period of 5-30 weeks. The initial dose (1.0 g/d) was increased weekly (by 1.0 g/d) until F-reticulocytes doubled. All patients showed an increase in F-reticulocytes (P = 0.002) that was dose-dependent (P = 0.001). Three of 5 patients who continued oral SPB for more than 10 weeks had substantial increases in HbF. We conclude that lower dose SPB is effective in inducing HbF synthesis in some children with HbSS. Further trials are warranted to determine the optimal treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468915     DOI: 10.1097/00043426-200212000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  14 in total

Review 1.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

2.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

3.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

4.  Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.

Authors:  Michael S Boosalis; Serguei A Castaneda; Marie Trudel; Rodwell Mabaera; Gary L White; Christopher H Lowrey; David W Emery; Marthe-Sandrine Eiymo Mwa Mpollo; Ling Shen; William A Wargin; Regine Bohacek; Douglas V Faller; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2011-08-15       Impact factor: 3.039

5.  Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Authors:  Sung Won Kim; Jacob M Hooker; Nicola Otto; Khaing Win; Lisa Muench; Colleen Shea; Pauline Carter; Payton King; Alicia E Reid; Nora D Volkow; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2013-07-29       Impact factor: 2.408

Review 6.  Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.

Authors:  Kristin Loiselle; Jennifer L Lee; Lauren Szulczewski; Sarah Drake; Lori E Crosby; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-09-18

7.  Role of STAT3 and GATA-1 interactions in gamma-globin gene expression.

Authors:  Xiao Yao; Sirisha Kodeboyina; Li Liu; James Dzandu; Jose Sangerman; Solomon F Ofori-Acquah; Betty S Pace
Journal:  Exp Hematol       Date:  2009-05-15       Impact factor: 3.084

8.  A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth Ataga; Marvin Reid; Elliott P Vichinsky; Lynne Neumayr; Loray Blair-Britt; Richard Labotka; Jonathan Glass; Jeffrey R Keefer; William A Wargin; Ronald Berenson; Susan P Perrine
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

Review 9.  Pharmacotherapy in sickle cell disease--state of the art and future prospects.

Authors:  Jane Hankins; Banu Aygun
Journal:  Br J Haematol       Date:  2009-02-17       Impact factor: 6.998

10.  The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.

Authors:  Sana Basseri; Sárka Lhoták; Arya M Sharma; Richard C Austin
Journal:  J Lipid Res       Date:  2009-12       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.